
Public Health Tools for Eliminating Hepatitis

David L. Thomas, MD, MPH Johns Hopkins Medicine


Chronic hepatitis is an important public health problem



Tools for eliminating hepatitis




Public health tools for eliminating hepatitis




Thomas Nat Med 2013


Public health tools for eliminating hepatitis




Public health tools for eliminating hepatitis




Public health tools may be sufficient






In some contexts new tools are needed




Tools to reduce annual number of new persons living with CHB 95%




WHO: Global Health Sector Strategies: HIV, STI and Hepatitis: 2022-2030

Blocking perinatal spread of HBV is key to control



*90% chosen by WHO De Villiers and Hallet Nat Comm 2021; Nayagam and Hallett Lancet ID 2016


Blocking perinatal spread of HBV is key to control



*90% chosen by WHO

De Villiers Nat Comm 2021; Nayagam Lancet ID 2016

Uneven uptake of the birth dose vaccination tool



WHO Global Progress Report 2021

New uses of tools may <u>help</u>eliminate hepatitis B when birth dose vaccination does not occur

Universal peripartum treatment

- WHO triple elimination initiative: testing 95% of pregnant women for HIV and syphilis*
- HBV treatment with tenofovir could be recommended
- May be efficacious supplemental tool
 - Models of Homie Razavi and Margaret de Villiars/Tim Hallett

2021 WHO Report on Elimination of Mother-to-Child-Transmission of HIV, syphilis and HBV. Thompson Lancet Global Health 2021; Lesi and Ward Lancet Global Health 2021; Funk Lancet ID 2020

*90% rec for HBsAg

New uses of tools may <u>help</u> eliminate hepatitis B when birth dose vaccination does not occur

Universal peripartum treatment

- All 4016 women agreed to HBsAg screening
- 90 pregnant women with chronic hep B in DRC (1 HIV pos)
- Of 88 infants born, 46 (52%) received timely birth dose vaccination
- 9/10 women HBeAg pos (n=9) and/or DNA>200,000 (n=5) given TDF
- 0/6 had expected TDF blood levels

Morgan MedRxiV 2023; Thompson Lancet Global Health 2021; Lesi and Ward Lancet Global Health 2021


New tools may <u>help</u>eliminate hepatitis B

- WHO triple elimination initiative: testing 95% of pregnant women for HIV and syphilis*
- HBV treatment with tenofovir could be uniformly recommended
- Might be efficacious when mother is HBeAg negative
- Long-acting TFV formulations
- Home birth dose vaccination

2021 WHO Report on Elimination of Mother-to-Child-Transmission of HIV, syphilis and HBV. Thompson Lancet Global Health 2021; Lesi and Ward Lancet Global Health 2021; Funk Lancet ID 2020


*90% rec for HBsAg

Tools to reduce persons dying from with CHB



WHO: Global Health Sector Strategies: HIV, STI and Hepatitis: 2022-2030


Testing and treatment needed to reduce HBV mortality



PPT- peripartum treatment

Nayagam Lancet ID 2016

Uneven uptake of testing and treatment tools



Percentage of hepatitis B infected persons diagnosed to end 2019


Percentage of hepatitis B infected persons treated to end 2019

WHO Global Progress Report 2021


New tools may help eliminate mortality among persons living with CHB

- Universal (not risk based) testing
- POC tools (home) for diagnosis and management
- Simpler guidance for treatment
- Alternative, affordable/available treatments
- Long-acting
- Cure

Tools to reduce annual number of new persons living with chronic HCV




WHO: Global Health Sector Strategies: HIV, STI and Hepatitis: 2022-2030



HCV incidence is rising fast in the USA because of opioid crisis

Rates of reported acute hepatitis C, by age group — United States, 2003–2018




Source: CDC, National Notifiable Diseases Surveillance System.

Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report – United States, 2020. <u>https://www.cdc.gov/hepatitis/statistics/2020surveillance/index.htm.</u> Published September 2022.

New tools and uses to eliminate new persons acquiring HCV


- HCV vaccine
 - CHIM
- Expansion of harm reduction
 - Integration of treatment
 - Decriminalization and destigmatization

Tools to reduce annual number of persons dying from chronic HCV%




WHO: Global Health Sector Strategies: HIV, STI and Hepatitis: 2022-2030

Declines in HCV mortality depend on expanding testing and treatment



Uneven uptake of testing and treatment tools



Percentage of hepatitis C infected persons diagnosed to end 2019

Percentage of hepatitis C infected persons treated to end 2019

WHO Global Progress Report 2021

New tools to reduce mortality in persons living with HCV


- Fast, affordable POC confirmation of diagnosis
- Self testing
- Treatment distribution in corrections and unreached places
- Long-acting 1x cures

Grebeley Lancet Gastro Hepatol 2017; Shilton S BMC Pub Health 2022

More new tools can help global elimination

More new tools can help global elimination

• Surveillance



Cooke Lancet Gastro Hep 2019

• Surveillance


• Patents, licensing, and pricing

- Surveillance
- Patents, licensing, and pricing
- Regulatory pre-approval


- Surveillance
- Patents, licensing, and pricing
- Regulatory pre-approval
- Politics

- Surveillance
- Patents, licensing, and pricing
- Regulatory pre-approval
- Politics
- Persons living with HBV and HCV


- Surveillance
- Patents, licensing, and pricing
- Regulatory pre-approval
- Politics
- Persons living with HBV and HCV
- Funding



Global hepatitis elimination requires more



Global hepatitis elimination requires more



Special Thanks















